Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01088347

Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer

A Phase 1b/2 Study With the Agonistic TRAIL-R1 Antibody, Mapatumumab, in Combination With Cisplatin and Radiotherapy as a First Line Therapy in Patients With Advanced Cervical Cancer.

Sponsor: Human Genome Sciences Inc.

Conditions Advanced Cervical Cancer

Interventions cisplatin mapatumumab radiotherapy

Updated 6 times since 2017 Last updated: Apr 17, 2024 Started: Mar 31, 2010 Primary completion: Mar 31, 2014 Completion: Mar 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Advanced Cervical Cancer, this trial is completed. The trial is conducted by Human Genome Sciences Inc. and has accumulated 6 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2024 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — May 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Human Genome Sciences Inc.
University Medical Center Groningen

Data source: University Medical Center Groningen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Groningen, Netherlands